Spero Therapeutics (SPRO) to Release Quarterly Earnings on Monday

Key Points

• Spero Therapeutics is set to announce its Q2 2025 earnings on August 4th, with analysts predicting an EPS of (–$0.35) for the quarter.
• The company reported a negative return on equity of 123.50% and a revenue of $5.87 million last quarter, which fell short of expectations.
• Spero Therapeutics currently holds a consensus rating of "Hold" from analysts, with an average target price of $5.00 per share.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.30. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. The company had revenue of $5.87 million for the quarter, compared to the consensus estimate of $11.00 million. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Stock Performance

SPRO stock traded up $0.22 during trading on Thursday, reaching $2.40. 755,140 shares of the company traded hands, compared to its average volume of 2,019,529. Spero Therapeutics has a 12 month low of $0.51 and a 12 month high of $3.22. The business has a 50 day simple moving average of $2.49 and a 200 day simple moving average of $1.36. The company has a market capitalization of $133.90 million, a price-to-earnings ratio of -1.87 and a beta of 1.33.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Spero Therapeutics to a "hold" rating in a report on Saturday, June 21st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $5.00.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.